NASDAQ:DRIO DarioHealth (DRIO) Stock Forecast, Price & News $3.28 +0.05 (+1.55%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$3.16▼$3.3050-Day Range$2.60▼$3.7452-Week Range$2.55▼$6.78Volume45,482 shsAverage Volume93,622 shsMarket Capitalization$89.31 millionP/E RatioN/ADividend YieldN/APrice Target$6.03 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media DarioHealth MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside83.9% Upside$6.03 Price TargetShort InterestBearish6.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.98) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.66 out of 5 starsMedical Sector872nd out of 972 stocksDiagnostics & Research Industry2nd out of 2 stocks 3.5 Analyst's Opinion Consensus RatingDarioHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.03, DarioHealth has a forecasted upside of 83.9% from its current price of $3.28.Amount of Analyst CoverageDarioHealth has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.02% of the outstanding shares of DarioHealth have been sold short.Short Interest Ratio / Days to CoverDarioHealth has a short interest ratio ("days to cover") of 14.9, which indicates bearish sentiment.Change versus previous monthShort interest in DarioHealth has recently increased by 2.50%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDarioHealth does not currently pay a dividend.Dividend GrowthDarioHealth does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DRIO. Previous Next 3.2 News and Social Media Coverage News SentimentDarioHealth has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for DarioHealth this week, compared to 1 article on an average week.Search Interest7 people have searched for DRIO on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows10 people have added DarioHealth to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DarioHealth insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.40% of the stock of DarioHealth is held by insiders.Percentage Held by InstitutionsOnly 33.31% of the stock of DarioHealth is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DarioHealth are expected to grow in the coming year, from ($1.98) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DarioHealth is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DarioHealth is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDarioHealth has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DarioHealth (NASDAQ:DRIO) StockDarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its user-centric multi-chronic condition digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Move to address most common MSK conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Read More DRIO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRIO Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comDario Publishes New Research Demonstrating Clinically Significant Reductions in Depression Through its Digital Behavioral Health ProgramsSeptember 27, 2023 | finance.yahoo.comDarioHealth Corp. (NASDAQ:DRIO) Shares Could Be 50% Below Their Intrinsic Value EstimateOctober 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 26, 2023 | americanbankingnews.comDarioHealth (NASDAQ:DRIO) Share Price Passes Below 50-Day Moving Average of $3.25August 24, 2023 | finance.yahoo.comDario Publishes New Research Demonstrating Greater Engagemenet and Improved Clinical Outcomes Sustainable for Two YearsAugust 17, 2023 | markets.businessinsider.comLifeSci Capital Keeps Their Buy Rating on DarioHealth (DRIO)August 15, 2023 | finance.yahoo.comDario Partners with PlanSource to Offer Employers Easy Access to Proven Digital Health SolutionsAugust 12, 2023 | finance.yahoo.comSome DarioHealth Corp. (NASDAQ:DRIO) Analysts Just Made A Major Cut To Next Year's EstimatesOctober 1, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 11, 2023 | msn.comAlliance Global Partners Maintains DarioHealth (DRIO) Buy RecommendationAugust 11, 2023 | finance.yahoo.comDarioHealth Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsAugust 10, 2023 | markets.businessinsider.comHere's what Wall Street expects from DarioHealth's earningsAugust 10, 2023 | finanznachrichten.deDarioHealth Corp.: DarioHealth Reports Second Quarter 2023 Financial and Operating ResultsAugust 10, 2023 | finance.yahoo.comDarioHealth Reports Second Quarter 2023 Financial and Operating ResultsAugust 8, 2023 | finance.yahoo.comDario Expands Partnership with Large Regional Health PlanAugust 4, 2023 | finance.yahoo.comThe past five years for DarioHealth (NASDAQ:DRIO) investors has not been profitableAugust 3, 2023 | finance.yahoo.comDarioHealth to Report Second Quarter 2023 Results on Thursday, August 10thAugust 3, 2023 | markets.businessinsider.comDarioHealth (DRIO) Gets a Buy from LifeSci CapitalAugust 2, 2023 | finance.yahoo.comDario Introduces GLP-1 Behavior Change Program to Help Achieve Weight Loss Goals and Better Overall Health OutcomesJuly 26, 2023 | msn.comStifel Maintains DarioHealth (DRIO) Buy RecommendationJuly 26, 2023 | finance.yahoo.comNew Research Shows $5,077 in Medical Costs Savings for Dario UsersJuly 24, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Buy Rating on DarioHealth (DRIO)July 24, 2023 | finance.yahoo.comDario Launches Agreement with Large Regional Health Plan and Announces Preliminary Results for Second Quarter of 2023 as well as Business UpdateJuly 8, 2023 | finance.yahoo.comDRIO - DarioHealth Corp.July 6, 2023 | finance.yahoo.comDario Announces New Full Suite Employer ContractJune 26, 2023 | finance.yahoo.comNew Research Demonstrates 2.3 Point Reduction in HbA1c for Dario Digital Health Users with Baseline HbA1c Greater Than 9 pointsJune 14, 2023 | markets.businessinsider.comPre-market Movers: EAST, CNVS, DRIO, AGRX, IVA…See More Headlines Receive DRIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter. Email Address DRIO Company Calendar Last Earnings8/10/2023Today9/30/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRIO CUSIPN/A CIK1533998 Webwww.mydario.com Phone(833) 914-3796Fax972-4770-4059Employees241Year Founded2011Price Target and Rating Average Stock Price Forecast$6.03 High Stock Price Forecast$8.00 Low Stock Price Forecast$4.10 Forecasted Upside/Downside+83.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,190,000.00 Net Margins-120.19% Pretax Margin-216.49% Return on Equity-40.09% Return on Assets-27.20% Debt Debt-to-Equity Ratio0.37 Current Ratio8.14 Quick Ratio7.41 Sales & Book Value Annual Sales$27.66 million Price / Sales3.23 Cash FlowN/A Price / Cash FlowN/A Book Value$3.12 per share Price / Book1.05Miscellaneous Outstanding Shares27,230,000Free Float24,670,000Market Cap$89.31 million OptionableNot Optionable Beta1.37 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Erez Raphael (Age 50)CEO & Director Comp: $978.76kMr. Richard A. Anderson (Age 54)Pres Comp: $998.42kMr. Zvi Ben David (Age 62)CFO, Treasurer & Sec. Comp: $429.05kDov OppenheimCo-Founder & Production ChiefJosh FischerSr. VP of Operations & ComplianceClaudia LeviContent & Communications Mang.Mary MooneyVP of MarketingLimor DreznerVP HR & Chief of StaffMr. Olivier R. Jarry (Age 62)Sr. VP of Strategy & Bus. Devel. Mr. Jean Christophe MuylHead of Commercialization North AmericaMore ExecutivesKey CompetitorsAlpha Healthcare Acquisition Corp. IIINASDAQ:ALPACarmell TherapeuticsNASDAQ:CTCXHealth Sciences Acquisitions Co. 2NASDAQ:HSAQCytosorbentsNASDAQ:CTSOMonogram OrthopaedicsNASDAQ:MGRMView All CompetitorsInsiders & InstitutionsGoldman Sachs Group Inc.Sold 15,874 shares on 8/15/2023Ownership: 0.136%XTX Topco LtdBought 16,711 shares on 8/15/2023Ownership: 0.061%Citadel Advisors LLCSold 18,300 shares on 8/15/2023Ownership: 0.000%Appian Way Asset Management LPBought 258,376 shares on 8/14/2023Ownership: 4.705%Marco Investment Management LLCBought 9,500 shares on 8/14/2023Ownership: 0.073%View All Insider TransactionsView All Institutional Transactions DRIO Stock - Frequently Asked Questions Should I buy or sell DarioHealth stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DRIO shares. View DRIO analyst ratings or view top-rated stocks. What is DarioHealth's stock price forecast for 2023? 2 analysts have issued twelve-month price objectives for DarioHealth's stock. Their DRIO share price forecasts range from $4.10 to $8.00. On average, they anticipate the company's share price to reach $6.03 in the next year. This suggests a possible upside of 83.9% from the stock's current price. View analysts price targets for DRIO or view top-rated stocks among Wall Street analysts. How have DRIO shares performed in 2023? DarioHealth's stock was trading at $4.28 on January 1st, 2023. Since then, DRIO shares have decreased by 23.4% and is now trading at $3.28. View the best growth stocks for 2023 here. When is DarioHealth's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our DRIO earnings forecast. How were DarioHealth's earnings last quarter? DarioHealth Corp. (NASDAQ:DRIO) announced its earnings results on Thursday, August, 10th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.06. The firm earned $6.15 million during the quarter, compared to the consensus estimate of $6.04 million. DarioHealth had a negative trailing twelve-month return on equity of 40.09% and a negative net margin of 120.19%. What guidance has DarioHealth issued on next quarter's earnings? DarioHealth updated its second quarter 2023 earnings guidance on Monday, July, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $6.00 million-$6.15 million, compared to the consensus revenue estimate of $6.73 million. What other stocks do shareholders of DarioHealth own? Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL). What is DarioHealth's stock symbol? DarioHealth trades on the NASDAQ under the ticker symbol "DRIO." How do I buy shares of DarioHealth? Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DarioHealth's stock price today? One share of DRIO stock can currently be purchased for approximately $3.28. How much money does DarioHealth make? DarioHealth (NASDAQ:DRIO) has a market capitalization of $89.31 million and generates $27.66 million in revenue each year. The company earns $-62,190,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. How many employees does DarioHealth have? The company employs 241 workers across the globe. Does DarioHealth have any subsidiaries? The following companies are subsidiares of DarioHealth: Labstyle Innovation Ltd., PsyInnovations Inc., PsyInnovations India Private Limited., Upright Technologies Inc., and Upright Technologies Ltd..Read More How can I contact DarioHealth? DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The official website for the company is www.mydario.com. The company can be reached via phone at (833) 914-3796, via email at ir@mydario.com, or via fax at 972-4770-4059. This page (NASDAQ:DRIO) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DarioHealth Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.